Transgene SA Total Liabilities
Transgene SA total liabilities. Based on the latest financial reports, Transgene SA (TNG) has total liabilities worth €17.09 Million EUR (≈ $19.98 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Transgene SA to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Transgene SA (1997–2025)
Total liabilities of Transgene SA from 1997 to 2025. This chart illustrates how Transgene SA's total liabilities have evolved over time, based on quarterly financial data. Explore TNG long-term investment intensity to see how much of total assets are deployed in long-term investments.
Transgene SA Competitors by Total Liabilities
The table below lists competitors of Transgene SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tjk Machinery Tianjin Co Ltd
SHE:300823
|
China | CN¥357.13 Million |
|
Asia Polymer Corp
TW:1308
|
Taiwan | NT$1.51 Billion |
|
Live Oak Acquisition Corp. V Class A Ordinary Shares
NASDAQ:LOKV
|
USA | $30.19 Million |
|
Deutsche Real Estate AG
F:DRE2
|
Germany | €98.68 Million |
|
VT GMP Co.Ltd
KQ:018290
|
Korea | ₩93.15 Billion |
|
Zippy Technology Corp
TW:2420
|
Taiwan | NT$1.69 Billion |
|
Lantronix Inc
NASDAQ:LTRX
|
USA | $41.06 Million |
|
NEOWIZ
KQ:095660
|
Korea | ₩103.67 Billion |
Liability Composition Analysis (1997–2025)
This chart breaks down Transgene SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see TNG total asset value.
Liquidity & Leverage Metrics
Transgene SA Total Liabilities Ratios Explained
Transgene SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Transgene SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Transgene SA (1997–2025)
The table below shows the annual total liabilities of Transgene SA from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €17.09 Million ≈ $19.98 Million |
-36.63% |
| 2024-12-31 | €26.97 Million ≈ $31.53 Million |
-8.90% |
| 2023-12-31 | €29.61 Million ≈ $34.61 Million |
+3.53% |
| 2022-12-31 | €28.59 Million ≈ $33.43 Million |
-17.42% |
| 2021-12-31 | €34.63 Million ≈ $40.48 Million |
-1.63% |
| 2020-12-31 | €35.20 Million ≈ $41.16 Million |
-29.28% |
| 2019-12-31 | €49.78 Million ≈ $58.20 Million |
-30.71% |
| 2018-12-31 | €71.84 Million ≈ $83.99 Million |
-1.29% |
| 2017-12-31 | €72.78 Million ≈ $85.09 Million |
-4.79% |
| 2016-12-31 | €76.45 Million ≈ $89.37 Million |
+2.86% |
| 2015-12-31 | €74.32 Million ≈ $86.89 Million |
+7.54% |
| 2014-12-31 | €69.11 Million ≈ $80.80 Million |
-0.16% |
| 2013-12-31 | €69.23 Million ≈ $80.93 Million |
+13.70% |
| 2012-12-31 | €60.89 Million ≈ $71.18 Million |
+16.71% |
| 2011-12-31 | €52.17 Million ≈ $60.99 Million |
+30.20% |
| 2010-12-31 | €40.07 Million ≈ $46.84 Million |
+33.11% |
| 2009-12-31 | €30.10 Million ≈ $35.19 Million |
-7.16% |
| 2008-12-31 | €32.42 Million ≈ $37.91 Million |
+86.58% |
| 2007-12-31 | €17.38 Million ≈ $20.32 Million |
+27.54% |
| 2006-12-31 | €13.63 Million ≈ $15.93 Million |
+20.92% |
| 2004-12-31 | €11.27 Million ≈ $13.17 Million |
-0.27% |
| 2003-12-31 | €11.30 Million ≈ $13.21 Million |
-3.20% |
| 2002-12-31 | €11.67 Million ≈ $13.65 Million |
-8.71% |
| 2001-12-31 | €12.79 Million ≈ $14.95 Million |
-2.76% |
| 2000-12-31 | €13.15 Million ≈ $15.37 Million |
+15.22% |
| 1999-12-31 | €11.41 Million ≈ $13.34 Million |
+0.77% |
| 1998-12-31 | €11.33 Million ≈ $13.24 Million |
+19.61% |
| 1997-12-31 | €9.47 Million ≈ $11.07 Million |
-- |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) posi… Read more